The deck opens with a forward-looking statements disclaimer, then a provocative title slide and a framing of obesity as a civilisation-scale health challenge. It moves through the GLP-1 revolution, the company's pipeline and its collaboration with Roche on petrelintide, and a roadmap toward a fully integrated biotech by 2030. Mid-deck sections cover unmet needs in weight management, consumer and prescriber segments, and treatment persistence. Later sections are presented by different speakers: survodutide in obesity and MASH with Phase 2 and Phase 3 data, an explainer on amylin biology and clinical evidence for amylin analogs, and petrelintide's amylin franchise. The closing sections cover the company's pipeline engine and how it funds and scales the business, followed by Q&A. Slides worth studying include the agenda dividers that repeat the running order with the current section highlighted, the dense pipeline table on slide 17, the segmented audience slides on 23 and 24, and the Phase 2 survodutide dose-response chart on slide 42. The deck relies heavily on clinical charts with footnoted sources and uses a consistent section-divider system throughout.
Slides worth studying




Questions about this deck
How many slides does the Zealand Pharma Capital Markets Day 2025 deck have?
The Zealand Pharma Capital Markets Day 2025 deck has 119 pages. Slide 1 is the title slide, Zealand Pharma Capital Markets Day 2025.
What does the Zealand Pharma deck say about its petrelintide collaboration with Roche?
Slide 7 states that Zealand Pharma has a collaboration and license agreement with Roche for petrelintide, including co-development and co-commercialization in the U.S. and Europe. Slide 8 describes the partnership as an equal partnership with a shared commitment to redefine obesity care.
What does the Zealand Pharma deck say about its pipeline and upcoming launches?
Slide 17 is titled Five launches in the next five years and lists the pipeline by area, including survodutide (GCGR/GLP-1R dual agonist) in obesity Phase 3 and MASH Phase 3. Slide 11 sets out key catalysts for 2026 to 2030, including Survodutide Ph3 obesity data (BI) and Petrelintide Ph2 data.
How many people does the Zealand Pharma deck say live with obesity today?
Slide 5 states that more than 1 billion people are living with obesity today. Slide 18 adds that 50% of adults globally are expected to live with overweight or obesity by 2030, citing the World Obesity Atlas 2024.
Details
- Company: Zealand Pharma
- Year: 2025
- Type: Investor presentation
- Industry: Biotech / Pharmaceuticals
- Pages: 119
Review score: 7 out of 10, Effective
Presentation quality, judged with the SlideDeck Co review heuristic. Ask, evidence and idea merit are not rated here.
The deck is a capital markets day presentation with a clear running order, repeated agenda dividers (14, 16, 36, 55) and a consistent identity: dark gradient openers, then light teal content slides with action titles. The data slides are strong; slide 42 has a clean dose-response chart with a direct legend, colour-matched value pills and a title that states the finding, and slide 17 organises the pipeline clearly. Weaknesses are consequential: several slides carry very small footnotes and sources (20, 26, 27, 52), the forward-looking statements slide 2 is unreadable, and the opening slides (5, 6, 7, 9) use tiny captions under large atmospheric art. Slides 23, 24 and 28 repeat the same segment slide three times with fading, and mid-deck sections run dense and uneven in style, with some imagery (3, 13, 38) that is striking but only loosely tied to the argument.
Worth keeping: Keep the action-title convention, the agenda divider that highlights the current section with speaker and time (14, 16), the pipeline table on 17 and the clean survodutide chart on 42 with colour-matched end-value pills.
Most useful repair: Enlarge the footnotes and source lines, and the tiny labels on slides 5, 6, 7 and 9, and trim the dense charts and tables on slides 20, 21, 44 and 52 so the key takeaway is readable at room distance.
What would change the score: I would make the biology and clinical slides in the amylin section (58 to 72) look more like the survodutide slides, and use the three-step segment build on 23, 24 and 28 only if it adds something beyond highlighting.
Confidence medium. 72 of 119 pages inspected on contact sheets, 4 at readable size. Reviewed 2026-11-08. Model-assisted review (claude-sonnet-5-5).
Full text of the slides (119 slides)
Every slide's words and a description of its charts and images, so the deck can be searched and rebuilt. Also available as Markdown.
Slide 1
Zealand Pharma
Capital Markets Day
2025
Visuals: Full-bleed photograph-style background of a dark curved abstract form: a large black sphere-like arc sweeps from the lower-left edge up to the upper-right, its rim lit by a glowing cyan-teal light band that is brightest at the top-right corner. Composition is wide and cropped, with the arc filling the lower-left and the glow in the upper-right. Lighting is a single cyan rim light against black. Dominant colours are black, deep teal and cyan (#19C3D0 at the glow peak). Not boxed; no overlay other than the natural darkening. One small logo at top-left: a row of five overlapping coloured circles reading Z, E, A, L and & in white letters on blue (#1F6FB5), grey (#9AA0A6), yellow-orange (#F5A623), teal (#1BA6A0) and red (#E5484D), with the words ZEALAND PHARMA in small white capitals beneath.
Slide 2
Forward-looking statements
This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company’s pre-clinical and clinical trials and the reporting of data therefrom and the company’s significant events and potential catalysts in 2025 and financial guidance for 2025. These forward-looking statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would” and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented.
The audience and readers of this presentation are cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to effect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty.
If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this presentation and are based on information available to Zealand Pharma as of the date of this presentation. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof unless required by law.
Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.
ZEALAND PHARMA
Visuals: One full-bleed dark abstract illustration fills the slide behind all text. On the right side a large near-black curved sheet rises from the bottom centre-right to the top-right corner, with a soft grey-to-black gradient. At the bottom right a glossy teal-cyan ribbon of light sweeps up and to the left from the bottom-right corner, with a bright white-cyan highlight along its upper edge and a teal glow fading into black. Composition is wide and uncropped at the slide edges, with no overlay or tint. Lighting is dim with a single bright rim highlight on the ribbon. Dominant colours are black #000000, near-black #0B0F10, and cyan #14C8D2. The Zealand Pharma logo at bottom left consists of five overlapping circles in blue #1F6FD1, grey #A7A9AC, yellow #F5B800, light blue #29B6E8 and red-orange #E8462F, each carrying a white letter Z, E, A, L and ampersand, with the white wordmark ZEALAND PHARMA beneath in bold sans-serif capitals.
Slide 3
Not a faster horse
Visuals: One photograph: a dark bay or black horse standing in a three-quarter view, head lowered toward the viewer and turned slightly left, with its mane falling over the forehead and a thin light highlight tracing the edge of the mane near the top of the head. The horse's body fades into darkness on the left and bottom. Composition: the horse fills most of the frame height, cropped at the bottom edge, with its ears and head near the upper-right third. Lighting: a single soft key light from the upper right, producing grey and silver highlights on the neck, shoulder and muzzle against a near-black background. Dominant colours: near-black #000000 and charcoal greys with warm brown tints in the mane. The photograph is boxed as a rectangle, not full-bleed, with its edges blending into the black background, and has no overlay or tint.
Slide 4
Redefining obesity for a new era
Line
Building a generational biotech company in metabolic health.
4
Visuals: Background illustration: a soft, out-of-focus abstract gradient of glowing teal and green curved bands on black. A bright teal arc sweeps across the top from the upper-left toward the upper-right, with its brightest part near the top-right corner. A second, dimmer teal band curves up along the right edge and sweeps into the bottom-right corner. The centre and left side are near-black. The image covers the whole slide, full-bleed, with no frame, crop shape or overlay. Lighting is a diffuse glow with no visible light source. Dominant colours are black #000000, teal #00C8A8 and deep green #006B55. One horizontal white rule (1 px-scale line, about #FFFFFF) with a small white filled dot at its right end, at about 66% of slide height.
Slide 5
Obesity: / requires a / civilization-scale / health shift
>1 billion people living / with obesity today
Rising for decades / without decisive action
Obesity is not an / individual failure
5
Visuals: One abstract illustration fills the whole slide: a large glowing ring or arc of golden-yellow light whose upper edge curves across the top-right, with a bright cream-white rim highlight along its top edge. The arc fades through dark amber-brown to black toward its lower boundary, which is a broad curve sweeping from the left edge near 80% of height up to the right edge near 45%. Composition is full-bleed, not cropped to a box, with no overlay. Lighting is a soft self-glow, dominant colours are black #000000, golden yellow #C9A800, dark amber #3A2A05 and cream #F5EFD0. Three white bullet dots (about 0.6% wide) sit at the start of each callout, each with a thin vertical white hairline (about 0.1% wide, #FFFFFF at full opacity) running from the dot down to the bottom edge of the slide.
Slide 6
The GLP-1 revolution / changed expectations / Double-digit weight / loss at scale / Obesity proven / as drug treatable / Expectations reset / for patients, systems / and markets / 6
Visuals: Illustration: a large, dark teal planetary horizon, a curved body whose top edge sweeps from the left edge at about 50% height down to the bottom-right at about 0% from the right edge near the bottom. Its surface is near-black teal shading into a soft cyan glow along the bottom centre, roughly between 20% and 65% of the width and the bottom 6% of the height, with a pale white-cyan rim light on the top of the glow. Lighting comes from below. The image covers the full slide, full-bleed, with no border or tint. Three thin white leader lines with white dots: dot 1 at about x 26.9%, y 40.0% with its line dropping to about y 60%; dot 2 at about x 49.7%, y 57.9% with its line dropping to about y 76%; dot 3 at about x 72.1%, y 77.2% with its line running to the bottom edge.
Slide 7
Petrelintide
A potential foundational therapy
Feel full faster
Designed for
high-quality,
durable weight
loss
Stand-alone and
in combo with CT-388
(GLP-1/GIP)
Zealand Pharma has a collaboration and license agreement with Roche for petrelintide,
including co-development and co-commercialization in the U.S. and Europe.
7
Visuals: One illustration covering the full slide: an abstract curved shape resembling the edge of a large dark sphere or lens, running from the top edge at about x 74% down to the bottom-right corner. Its upper-right section glows bright cyan (#1FC8D6-like) with a white highlight along the top arc, fading into very dark teal (#0B2B2E) and near-black toward the lower right. The shape is not boxed and has no overlay beyond the black background at the left. Three thin white horizontal lines (about 1 px) with white filled dots at their ends connect the left edge to the three labels: first line at y 46.2% ending at a dot at x 55.3%; second line at y 60.2% ending at a dot at x 32.1%; third line at y 80.2% ending at a dot at x 49.5%. Each dot is about 0.6% of slide width in diameter.
Slide 8
Biotech speed,
pharma strength
Equal partnership with a
shared commitment to
redefine obesity care
Unites Zealand Pharma’s
metabolic heritage with
Roche’s manufacturing
and commercial
infrastructure
Zealand Pharma to
build U.S. launchpad for
petrelintide and future
metabolic health
medicines
Teresa Graham, CEO, Roche Pharmaceuticals and
Adam Steensberg, CEO, Zealand Pharma. October 2025
8
Visuals: Black-and-white photograph of two seated people on a grey upholstered sofa in front of a window-lit room with ceiling lights. Left: Teresa Graham, a smiling woman with glasses, shoulder-length light-brown hair, dark blazer over white top, hands clasped in lap. Right: Adam Steensberg, a smiling man with short greying hair, dark suit jacket, open-collar white shirt, hands clasped, a small lapel microphone visible. Photo is boxed at the left edge, full height, with a darkened gradient at the bottom where the caption sits; the image is cropped at the frame edges. Lighting is soft and diffuse with bright ceiling lights and window highlights. Dominant colours are greys and black. Right side of the slide has a large curved yellow-to-black glowing arc shape running from top right edge down to the right edge near 70% height, with a soft gold highlight. Logos: ZEAL& ZEALAND PHARMA logo in white (circular letter badges with the word ZEALAND PHARMA beneath) at about x 62 y 71 w 6.6 h 6.2 region; Roche logo in white hexagon outline with the word Roche inside at about x 74.5 y 71 w 6.6 h 6.2. A thin white horizontal line with a small filled white dot at its left end runs from about x 62 at y 79.5 to the right edge.
Slide 9
A generational / biotech in / metabolic / health
By ‘generational’ we mean:
We will shape / obesity care / for decades, / not cycles
Through a / platform and / exceptional / pipeline, not / a single product
With multiple / waves of / innovation / in metabolic / health
9
Visuals: Background photograph-like blurred gradient, not a chart or diagram. Soft out-of-focus amber/ochre curved light band sweeping from the lower left (around y 75-100%, x 0-40%) and a second broad warm glow curving from the centre to the lower right, over a black base. The upper-right corner has a faint dark maroon and olive tint. Full-bleed, covering the whole slide, with no overlay beyond the gradient itself. Three thin white vertical hairlines run from each bullet dot down to the bottom edge of the slide at x about 49.2%, 66.1% and 83.3%, each beginning at y about 54.8% with a small filled white dot (about 1% of slide width) on top. Hairlines are about 0.1% of width, white at reduced opacity.
Slide 10
An engine built on / peptides, data and AI
METABOLIC FRONTIER 2030
By 2030:
•5 launches in 5 years
•10+ clinical programs in / metabolic health
•Industry-leading cycle / times from idea to clinic
Our unfair advantage in / metabolic health
Unmatched expertise in peptides / and metabolic health
+
>25 years of rich / proprietary data
+
Unique opportunity to leverage AI/ML
10
Visuals: A thin white horizontal line with a small arrowhead at its right end, running from about x 42.9% to x 98.5% at y about 39.7%, passing across the right column just above the bullets. A full-bleed dark photographic-style background (see background) with a glowing teal-green curved arc rising from the bottom right. Teal plus-sign glyphs (#23AEB7) appear twice inside the left panel, one between the first and second items and one between the second and third items. No charts, tables or logos.
Slide 11
Clear path to long-term value creation / with transformational milestones ahead / NON-EXHAUSTIVE / Key catalysts / Survodutide Ph3 obesity data (BI) / Petrelintide Ph2 data / Petrelintide Ph3 initiation / Petrelintide/CT-388 Ph2 initiation / Kv1.3 Ph1 data and Ph1b initiation / Dasiglucagon/CHI U.S. regulatory submission / New Ph1 program(s) / Survodutide Ph3 MASH data (BI) / Survodutide launch in obesity (BI) / Survodutide launch in MASH (BI) / Petrelintide Ph3 data / Petrelintide/CT-388 Ph2 data / Petrelintide Ph3b initiation, incl. CVOT / Kv1.3 Ph1b data and Ph2 initiation(s) / Dasiglucagon/CHI launch (partner) / Glepaglutide/SBS Ph3 topline data / Multiple new Ph1 and Ph2 programs / Petrelintide launch in obesity / Petrelintide/CT-388 Ph3 initiation / Glepaglutide/SBS launch (partner) / Kv1.3 Ph2 data and Ph3 initiation(s) / Multiple new Ph1, Ph2 and Ph3 programs / Operations / Establish Boston research site / Scale U.S. medical affairs and / commercial footprint / Survodutide royalty stream commencing / U.S. medical affairs and commercial / operations fully established / Petrelintide 50/50 profit share / Today / 2026 / 2027/2028 / 2029/2030 / 11 / Disclaimer: All follow-on activities and events are subject to final decision and contingent upon outcomes from ongoing and prior trials and other activities. Progression, sequencing, and timing are dependent on successful completion and evaluation / of earlier activities, some of which have not yet been initiated. / CHI=congenital hyperinsulinism; MASH=metabolic dysfunction-associated steatohepatitis; SBS=short bowel syndrome; BI=Boehringer Ingelheim; CVOT=cardiovascular outcomes trial.
Visuals: A three-column milestone diagram with a horizontal timeline. Each column holds translucent light-teal panels (fill #D2EEF0 at 20% opacity) containing stacked horizontal bars. Key catalyst bars are #22ADB7 teal, most at 50% opacity, while launch milestones are at full #22ADB7 opacity with black text. Column 1 (Today to 2026): 7 key catalyst bars; the bottom operations panel holds one bar, Establish Boston research site, in a dark translucent bar. Column 2 (2027/2028): 10 key catalyst bars, of which Survodutide launch in obesity (BI), Survodutide launch in MASH (BI) and Dasiglucagon/CHI launch (partner) are highlighted at full opacity; the operations panel holds two black translucent boxes (#000000 at 47% opacity), Scale U.S. medical affairs and commercial footprint and Survodutide royalty stream commencing. Column 3 (2029/2030): 5 key catalyst bars, of which Petrelintide launch in obesity and Glepaglutide/SBS launch (partner) are highlighted; the operations panel holds two black boxes, U.S. medical affairs and commercial operations fully established and Petrelintide 50/50 profit share. The timeline is a thin white horizontal line with four white circular dots at Today (11%), 2026 (about 38.7%), 2027/2028 (about 67.2%) and 2029/2030 (about 94.6%), each labelled below the line. The side labels Key catalysts and Operations are rotated 90 degrees in bold white.
Slide 12
The culture that delivers generational biotech for patients / Patient-driven & science-first: / Every decision anchored in metabolic biology & patient impact / Small, accountable, owner mindset: / Lean teams, clear ownership, no passengers / Data-native & collaborative: / Turning >25 years of data into better solutions with partners
Visuals: Three greyscale photographs, each a plain rectangle with sharp corners and no border, all the same size (about 17.9% of slide width by 26.2% of slide height). Photo 1 (upper, centre-right, x 51.4%, y 9.3%): two people in white lab coats at a lab bench with pipettes; a man in glasses on the left looks down at a small object in his hands, and an older woman with grey hair and glasses on the right holds a pipette; a bright window and white cabinets fill the background; soft natural daylight from the upper right; mid-grey and white tones. Photo 2 (lower, centre, x 27.9%, y 45.8%): three people seated at a desk with a computer monitor and keyboard; a woman with shoulder-length hair on the left works at a laptop, a smiling woman with long dark hair is in the middle, and a young man in a dark jumper is in the foreground on the right looking to the left, with a wristwatch visible; a window light background; medium contrast greyscale. Photo 3 (lower right, x 73.4%, y 45.7%): a woman with a ponytail in a white lab coat works at a laboratory liquid chromatography instrument stack with a label reading LC/MS 1200 and small tubes and bottles on top; the instrument is in the left half and she is in the right half; cool greyscale, high contrast, bright white coat. All three photos are fully visible, unbordered and not cropped in a circle; no overlay or tint is applied, although they are desaturated to greyscale. Also a decorative glowing teal arc in the lower left, described under elements.
Slide 13
Move Like
a Biotech,
Hit Like a
Pharma
Visuals: Photograph: a black-and-white boxing ring scene in a dark arena. In the centre a shirtless boxer stands on the ring apron with both gloved arms raised straight up, fists clenched, face turned slightly up and to the viewer's left, wearing white boxing boots and white trunks with a dark waistband bearing white lettering. To the left a man in a white shirt and dark trousers stands half-turned, looking toward the camera. To the right a referee in a white shirt, dark tie and dark trousers stands with a white towel knotted at his waist. Ring ropes run diagonally across the frame. In the foreground, seated photographers and spectators in the bottom right hold cameras, and a row of heads is visible along the bottom left. Ceiling spotlights and small round ceiling lights are visible at the top. Lighting is high-contrast, from overhead and the spotlights, with the boxer lit most strongly; the canvas floor is light grey at the bottom. Composition: a wide 16:9 frame, boxer centred and vertically dominant, photo full-bleed with no crop box. Overlay: a dark vignette darkens the corners and edges. Dominant colours: black, white and greys (monochrome). Line: a single thin white rule, about 0.1% of slide height thick, with small round dots at both ends, sitting across the lower part of the text, behind nothing but over the photo.
Slide 14
Today’s journey:
how the story unfolds
1.
The opportunity
& our ambition
Adam Steensberg
1:05-1:25
3.
Survodutide: the next
frontier in obesity
& MASH (GCG/GLP-1)
Carel Le Roux & David
Kendall - including Q&A
1:50-2:25
Break
3:05-3:45
6.
Our engine: world’s
most valuable
metabolic health
pipeline
Utpal Singh
4:20-4:50
8.
Q&A and
closing remarks
Adam Steensberg
& team
5:00-5:30
2.
The future of
weight management
Eric Cox
1:25-1:50
4.
Amylin: an emerging
therapeutic class
Jonathan D. Roth
& Louis J. Aronne
2:25-3:05
5.
Petrelintide: building the
leading amylin franchise
David Kendall
- including Q&A
3:45-4:20
7.
How we fund
and scale this
Henriette Wennicke
4:50-5:00
14
Visuals: Background photograph-style illustration covering the full slide: near-black field with a bright teal-cyan curved glowing arc (a planet limb or ring edge) entering from the top right corner and sweeping down toward the right edge around y 30%, with a soft dark-teal haze and a faint curved light edge at the bottom left corner. Composition is full-bleed with the glow cropped by the top and right edges. Lighting is a single rim-like glow. Dominant colours: #000000 black, #1FB5BF teal, #A8F4F8 pale highlight. Horizontal hairline across the slide at about 60.4% height in light grey-white, nine vertical stems and nine white dots on that line; no charts, tables or logos.
Slide 15
Maximize this / metabolic / moment / Obesity will define / the next decades / of healthcare / Catalyst-rich 2026 igniting / transformational journey / toward 2030 and beyond / We will become a / generational biotech / by building the world’s / most valuable metabolic / health pipeline / The opportunity now: / Zealand Pharma on the / cusp of transforming the / game for patients and / HCPs / 15
Visuals: A photograph-like illustration fills the full slide behind all text: a large dark curved planet or sphere edge occupies the left and lower-left, bounded by a diagonal limb running from top-left (about x 5%, y 0%) down to bottom-centre (about x 36%, y 100%). Along the lower-left limb a bright teal-cyan glowing arc sweeps from the left edge at about y 82% down to the bottom edge near x 28%, with a white highlight along its top edge. The remainder is near-black. Dominant colours are black, deep teal-black and bright cyan #1FC4C8. Lighting is a rim glow from the lower left. The image is full-bleed and not boxed, with no overlay or tint. Four thin teal vertical connector lines (stroke about 1 px, colour #2A9D8F) each end at a teal filled dot (diameter about 1.2% of slide width, colour #1AB0B5): line 1 at x 38.2%, y 0% to 16%, dot at x 38.0%, y 15.9%; line 2 at x 66.6%, y 0% to 33.8%, dot at x 66.2%, y 33.3%; line 3 at x 43.6%, y 48.9% to 100%, dot at x 43.4%, y 48.6%; line 4 at x 72.1%, y 66.4% to 100%, dot at x 72.0%, y 66.2%. The lines run to the slide edge and are cropped by it.
Slide 16
2.
The future
of weight
management
Eric Cox – 1:25-1:50
1.
The opportunity
& our ambition
Adam Steensberg
1:05-1:25
3.
Survodutide: the next
frontier in obesity
& MASH (GCG/GLP-1)
Carel Le Roux & David
Kendall - including Q&A
1:50-2:25
Break
3:05-3:45
6.
Our engine: world’s
most valuable
metabolic health
pipeline
Utpal Singh
4:20-4:50
8.
Q&A and
closing remarks
Adam Steensberg
& team
5:00-5:30
2.
The future
of weight
management
Eric Cox
1:25-1:50
4.
Amylin: an emerging
therapeutic class
Jonathan D. Roth
& Louis J. Aronne
2:25-3:05
5.
Petrelintide: building the
leading amylin franchise
David Kendall
- including Q&A
3:45-4:20
7.
How we fund
and scale this
Henriette Wennicke
4:50-5:00
ZEALAND PHARMA
Visuals: Background: a dark abstract gradient with a soft teal glow in the top-right corner and a broad teal arc along the bottom centre-right, fading to black; no photograph or people. Timeline: one thin horizontal off-white line (#B0B0B0, about 0.1% of slide height) running full width at about 63.6% height, with small white dots (#FFFFFF, about 0.5% diameter) at each junction. Vertical tick lines (#B0B0B0, 1px) rise above the line for items 1, 3, Break, 6 and 8, and drop below it for items 2, 4, 5 and 7, each ending at its text block. Highlight: a rectangle filled #FFFFFF at 20% opacity behind item 2, below the line, sharp corners. Logo: Zealand Pharma logo with five overlapping-free rounded-square letter tiles in a row: Z blue #1E63B6, E grey #A8A9AD, A yellow #F5B400, L teal #22ADB7, & red-orange #E8442E, with the wordmark ZEALAND PHARMA in white bold capitals beneath.
Slide 17
Five launches in the
next five years
Obesity and related comorbidities
Rare disease
Product candidate a
Product candidate a
Petrelintide
(amylin analog) b
Obesity
Phase 2
Petrelintide/CT-388
(amylin + GLP-1/GIP) b
Obesity
Phase 2-ready
Survodutide
(GCGR/GLP-1R dual agonist) c
Obesity
Phase 3
Dasiglucagon:
SC continuous infusion
Congenital hyperinsulinism
Registration
Glepaglutide
(GLP-2 analog)
Short bowel syndrome
Phase 3
Inflammation
Product candidate a
Survodutide
(GCGR/GLP-1R dual agonist) c
MASH
Phase 3
ZP6590
(GIP receptor agonist)
Obesity
Phase 1-ready
ZP9830
(Kv1.3 ion channel blocker)
Undisclosed
Phase 1
Dapiglutide
(GLP-1R/GLP-2R dual agonist)
Obesity
Paused (Phase 2-ready)
ZP10068
(complement C3 inhibitor)
Undisclosed
Pre-clinical
a Investigational compounds whose safety and efficacy have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.
b Zealand Pharma has a collaboration and license agreement with Roche for petrelintide, including co-development and co-commercialization in the U.S. and Europe.
c Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally.
GCGR=glucagon receptor; GIP=gastric inhibitory polypeptide; GLP-1R=glucagon-like peptide-1 receptor; GLP-2R=glucagon-like peptide-2 receptor; MASH=metabolic dysfunction-associated steatohepatitis; SC=subcutaneous.
17
ZEALAND PHARMA
Visuals: Seven pill-shaped product rows are shown as bars, not a chart. Left column: six rows, each a black left segment with white bold and regular text, a white middle segment with indication text and an optional partner logo, and a right grey segment holding the phase. Right column: four rows in two groups. Dasiglucagon and Glepaglutide use teal #23AEB7 left segments with white middle segments and teal text. ZP9830 and ZP10068 use grey #898D8D left segments with grey text in the middle and right segments. Logos: Zealand Pharma with Roche (a blue hexagonal Roche wordmark beside the Zealand Pharma wordmark) appears in the Petrelintide and Petrelintide/CT-388 rows at about x 31.4 to 37.0%. Boehringer Ingelheim (green emblem with serif wordmark) appears in the Survodutide Obesity and MASH rows at about x 31.8 to 37.4%. A Zealand Pharma logo (coloured circles Z, E, A, L, & with ZEALAND PHARMA beneath) appears bottom-left in the footer. A faint teal light streak sits in the top-right corner.
Slide 18
Obesity: greatest healthcare
challenge of our time
The obesity epidemic has surged over the past decades, with
50% of adults globally expected to live with overweight or obesity by 2030¹
>200 complications and comorbidities associated with obesity²
Today, ~35% of U.S. children and adolescents aged 2–19 years
live with overweight or obesity³
Sources: ¹World Obesity Atlas 2024; ²American Medical Association 2024: https://www.ama-assn.org/topics/obesity; ³CDC Childhood Obesity Facts (April 2024).
18
Visuals: Full-bleed photograph of a large dense crowd of people seen from behind, facing a dim stage in a dark auditorium, with heads filling the lower two thirds and stage structure and lighting in the darker upper area. It is tinted by a teal overlay, so the dominant colours are teal #23AEB7 and deep blue-teal shadows. Three white circular badges (about 180 px in diameter on a 2000 px wide slide, each with a faint translucent halo ring) each hold a teal line icon. Icon 1 (x 7.5%, y 25.6%, w 5.5%, h 9.3%) shows an upward trend arrow over clusters of small person figures. Icon 2 (x 7.3%, y 47.1%, w 6.3%, h 11.1%) is a 2x2 group of line icons: a heart, a liver, a brain and a lower-body or torso outline with a highlighted region. Icon 3 (x 6.9%, y 70.7%, w 6.7%, h 6.8%) shows four standing figures in a row, adults and children. Two white horizontal divider lines, each about 0.2% of slide height. No charts, tables or photographs inside the badges.
Slide 19
Unique disease area
Obesity
1
The consumer as key decision driver
a
2
Unprecedented size and scale
3
Two key healthcare providers:
Primary care and specialty care
4
Heterogeneity and fragmentation
5
Linked to many comorbidities
a Medicinal products remain prescription only. Ultimate decision maker remains the treating physician.
19
Visuals: Five-step process diagram. Circles 1 to 5 sit on a teal arc drawn across the right edge of a circular photo. Each circle has a dashed teal arrow pointing right to a line icon. Icon 1 is a person with arrows up and boxes with X and check marks. Icon 2 is a mountain with a flag on the peak. Icon 3 is two crossing arrows, a shuffle symbol. Icon 4 is a hand holding a puzzle piece. Icon 5 is a group of three line icons: a heart above, with a brain at lower left and a liver at lower right. Photo: a circular crop, about 846 by 846 pixels, of a white measuring tape wound across a pale, teal-tinted surface, with its numbers visible at the top and lower left. The photo is cropped to a circle, has a soft pale-teal wash over it, and is set on a near-white background. Lighting is soft and even. Dominant colours are white, pale aqua and light teal. The word Obesity is set over the photo in bold teal. Logo: the Zealand Pharma logo, with five coloured letter circles spelling ZEAL& in blue, grey, yellow, teal and red, and the words ZEALAND PHARMA below in navy.
Slide 20
Public health challenge:
We must improve treatment penetration and maintenance
BMI distribution and GLP-1 usage today a,1-3
High
Overweight
Obesity
Share of population (%)
Treated with GLP-1: / ~3% of eligible people in the U.S. 2
Have been exposed to GLP-1: / ~12% of Americans 4
Low
15 / 20 / 25 / 30 / 35 / 40 / 45 / 50 / 55
BMI
a Chart is illustrative. The general population BMI is modeled based on national public health statistics from a large, developed market.
Sources: 1 Distribution of Body Mass Index Among Adults (2024), https://www.kff.org/state-health-policy-data/state-indicator/distribution-of-body-mass-index-among-adults, accessed November 2024; 2 Kim et al. (2025) Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US, JAMA. Published online April 29, 2025; 3 World Obesity Atlas 2025. World Obesity. https://data.worldobesity.org/publications/world-obesity-atlas-2025-v7.pdf. Accessed November 2025; 4 Bozick et al (2025) GLP-1 agonist use and side effects in the United States. RAND. Published August 5, 2025.
BMI=body mass index; GLP-1=glucagon-like peptide-1.
20
Visuals: Chart: combined column and area chart titled BMI distribution and GLP-1 usage today, with superscript citations a,1-3. X axis labelled BMI, running from 15 to 55 in steps of 5, with tick labels at 15, 20, 25, 30, 35, 40, 45, 50, 55. Y axis labelled Share of population (%) with only the end labels Low at the bottom and High at the top; no numeric values are printed, so all heights are approximate. Series 1 (grey #D5D4D4 columns, about 70 percent opacity) covers BMI 15 to 24, rising from about 5 percent of the height at 15 to a peak near 24. Series 2 (light teal #23AEB7 columns at 10 percent opacity) covers BMI 25 to 55, peaking about 27 to 28 and falling to near zero by 55. Series 3 is a darker teal #23AEB7 area at 25 percent opacity overlaid on the light columns, peaking near BMI 37 at about 20 percent of the height, and a more saturated teal #23AEB7 area at 80 percent opacity along the base, peaking near BMI 38 at about 5 percent of the height; these areas show treated GLP-1 users (about values). Legend at right inside the plot: dark teal square labelled Treated with GLP-1: ~3% of eligible people in the U.S. (superscript 2); pale teal square labelled Have been exposed to GLP-1: ~12% of Americans (superscript 4). Above the plot a horizontal segmented teal bar #23AEB7 divided by thin white dividers into three labelled spans: unlabelled span from BMI about 15 to 30, Overweight span from about 25 to 30, and Obesity span from about 30 to 55. Axes: navy #002C52 L-shaped axis lines with arrowheads on the vertical and horizontal axes. Logo: Zealand Pharma logo at bottom left, five coloured circles with white letters Z E A L and ampersand in blue, grey, yellow, teal and red, with the words ZEALAND PHARMA beneath in grey.
Slide 21
Beyond Weight loss Olympics:
key unmet needs
First wave of incretins
New mechanisms and next-gen incretins
Better understanding of gut–brain axis biology
Unlocked the development of incretins
Focus on key unmet
medical needs and
weight loss experience
Narrative has centered
on magnitude and
speed of weight loss
Zepbound®
(2023)
Wegovy®
(2021)
Saxenda®
(2015)
Contrave®
(2014)
Qsymia®
(2012)
Scientific progress in weight management
1st
Inflection
point
2nd
Inflection
point
Time
Acceptability
Comorbidities
Weight
maintenance
Addressing key
unmet medical
needs
Quality of
weight loss
Usability
21
Visuals: Line chart, title none. Y-axis labelled 'Scientific progress in weight management' with no units or numeric range, rising upward with an arrowhead. X-axis labelled 'Time' with a rightward arrowhead, no tick values. One black curve: flat near the baseline from the left, rising steeply after the second inflection toward the top right, then continuing as a dashed teal segment. Dotted vertical drop lines at Qsymia (2012), Contrave (2014), Saxenda (2015), Wegovy (2021), Zepbound (2023), a first inflection marker and a second inflection marker. Red up-arrows mark the 1st inflection point (near Wegovy) and the 2nd inflection point (on the steep rise). No legend. Highlighted points are the two red inflection markers. Speech bubbles: black bubble 'Narrative has centered on magnitude and speed of weight loss' pointing to Wegovy; teal bubble 'Focus on key unmet medical needs and weight loss experience' pointing to the curve. Ring of five teal filled circles, each with a white line icon: shield with check mark (Acceptability, top), weight scale with footprints (Weight maintenance, upper right), flexed arm (Quality of weight loss, lower right), thumbs-up hand (Usability, lower left), and internal organs including brain, heart, liver and lungs (Comorbidities, upper left). Each circle has a pale teal halo and sits on a pale teal ring; the centre reads 'Addressing key unmet medical needs'. Logo: ZEAL& multicoloured letter circles (Z dark blue, E grey, A yellow, L teal, & red) with 'ZEALAND PHARMA' beneath.
Slide 22
Obesity demands
new classes of drugs
Hypertension
Dyslipidemia
Type 2 diabetes
Obesity
• Diuretics
• Beta-blockers
• ACE inhibitors
• ARBs
• Calcium channel blockers
• Direct renin inhibitors
• Vasodilators
• Centrally acting agents
• Statins
• Cholesterol absorption
inhibitors
• PCSK9 inhibitors
• Bile acid sequestrants
• PPAR-α agonists
• Nicotinic acid
• Omega-3 fatty acids
• ANGPTL3 inhibitors
• Metformin
• Sulfonylureas
• Meglitinides
• DPP-4 inhibitors
• SGLT-2 inhibitors
• GLP-1 receptor agonists
• Insulin
• Amylin (short-acting)
• GLP-1RA-based therapies
(GLP-1 and GLP-1/GIP)
+8
+8
+8
Only 1
+8 classes of drugs in other chronic disease areas with more mature and saturated markets
One class of drugs available today
Treatment options shown are not exhaustive.
ACE=angiotensin-converting-enzyme; ANGPTL3=angiopoietin-like protein 3; ARB=angiotensin receptor blocker; DPP-4=dipeptidyl peptidase 4; GLP-1=glucagon-like peptide-1; GIP=glucose-dependent insulinotropic polypeptide; GLP-1RA=glucagon-like peptide-1 receptor agonist; PCSK9=proprotein convertase subtilisin/kexin type 9; PPAR-α=peroxisome proliferator-activated receptor alpha; SGLT-2=sodium-glucose cotransporter-2; MoA=mechanism of action.
22
Visuals: No photograph. The background is a soft gradient image (1600 by 900 pixels, full-bleed) fading from near-white at the top left to pale aqua at the top right and to a teal wave shape across the bottom right. Four teal circle badges, all filled #23AEB7 with white bold text: three '+8' circles, each about 7.6% wide and 13.6% tall, centred under the Hypertension, Dyslipidemia and Type 2 diabetes bullet lists, and one larger 'Only 1' circle about 12.3% wide and 21.8% tall, centred under the Obesity column and overlapping the bottom edge of the grey panel. Two timelines: a black 1-pixel horizontal line with black dot end caps at each end, the first running from about x 5.3% to 70.7% at y 76.6%, and the second from about x 72.0% to 95.4% at the same height, each beneath its panel. Logo: Zealand Pharma logo at bottom left, five overlapping circles reading Z, E, A, L and & in blue, grey, yellow, teal and red, with the words ZEALAND PHARMA in small bold navy capitals below them.
Slide 23
Two distinct segments,
two focus areas
Prescriber-driven
Consumer-driven
Specialist-driven prescriptions focusing on benefits of
treating comorbidities and health impact of weight loss
Consumer-driven primary care prescriptions
focusing on desired weight loss and user experience
Objectives:
1 Comorbidity risk reduction and health outcomes
2 Relative weight loss
3 Tolerability and user experience (to improve persistence)
4 Convenience of treatment
Objectives:
1 Desired weight loss
2 Tolerability and user experience
3 Health outcomes
4 Convenience of treatment
23
Visuals: Two line-art illustrations in teal outline style, drawn in a single stroke with no fill. Left: a stylised female clinician in head-and-shoulders view, front-facing, with shoulder-length hair, a stethoscope hanging from the neck and a plain face with no features; sits inside the left card at about x 7.0 to 14.1 percent and y 25.3 to 40 percent. Right: a stylised male figure in head-and-shoulders view, front-facing, short hair, plain face with no features, no props; sits inside the right card at about x 53.2 to 60.6 percent and y 24.9 to 39.6 percent. Both figures are cropped at the bottom edge of the drawing, with shoulders fading out at the base. Also a faint teal-to-white light gradient glow in the top-right corner of the slide. Two dashed teal divider lines, one under each intro sentence.
Slide 24
Two distinct segments,
two focus areas
Prescriber-driven
Specialist-driven prescriptions focusing on benefits of
treating comorbidities and health impact of weight loss
Objectives:
1 Comorbidity risk reduction and health outcomes
2 Relative weight loss
3 Tolerability and user experience (to improve persistence)
4 Convenience of treatment
Consumer-driven
Consumer-driven primary care prescriptions
focusing on desired weight loss and user experience
Objectives:
1 Desired weight loss
2 Tolerability and user experience
3 Health outcomes
4 Convenience of treatment
24
Visuals: Two line-art illustrations. Left: a female clinician icon drawn in a thin teal (#23AEB7) single-weight outline, head-and-shoulders, with a neck stethoscope hanging from the collar, no fill, centred vertically in the left card at about x 7 to 14 and y 25 to 40. Right: a faded male figure outline in very pale grey-teal (about #D9E9EA) with a simple head, hair and shoulders silhouette, no fill, at about x 53 to 61 and y 25 to 40. The slide background photograph carries a soft cyan (#7FE3E8 fading to white) light glow in the top-right corner, unboxed and full-bleed. Two bold-free teal dashed divider lines sit under the descriptions: left solid-looking dashes in #23AEB7, right dashes in pale teal about #B9E6E9. The Zeal& logo is shown bottom left. No charts or tables.
Slide 25
Obesity impacts several / organ systems / NON-EXHAUSTIVE / Musculoskeletal and mechanical / Liver and gut / Cardiovascular / Overweight / and obesity / CNS and mental health / Endocrine / Renal / Source: American Medical Association 2024: https://www.ama-assn.org/topics/obesity. / CNS=central nervous system. / 25 / ZEALAND PHARMA
Visuals: Hub diagram (kind: diagram) with a light teal circular ring and six teal circular nodes placed at clock positions around it. Node 1 at top shows a bent knee/joint icon with impact marks, labelled Musculoskeletal and mechanical. Node 2 at upper right shows a liver with spots, labelled Liver and gut. Node 3 at lower right shows a brain, labelled CNS and mental health. Node 4 at bottom shows two kidneys, labelled Renal. Node 5 at lower left shows a pancreas, labelled Endocrine. Node 6 at upper left shows a heart, labelled Cardiovascular. The centre of the ring carries the text Overweight and obesity. Each node is a solid teal circle with a pale teal halo and white line icons. No chart values or photographs. Logo: Zeal& Zealand Pharma logo with five coloured circles spelling Z E A L and ampersand in dark blue, grey, yellow, teal and red, with ZEALAND PHARMA wordmark beneath.
Slide 26
Urgent need for better / treatment options in MASH / Survodutideᵃ holds potential to revolutionize treatment of MASH / and establish a strong foothold in the prescriber-driven segment / People who are / overweight or have / obesity / MASLD / ~75%¹ / ~34%¹ / T2D / MASH / ~15–30%²˒³ / ~10–15%⁴ / CVD / CKD / ~20%⁵˒⁶ / “See Obesity, Think Liver” / Boehringer Ingelheim at ObesityWeek 2025. / 26 / ᵃSurvodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally. / Sources: ¹Quek et al. Lancet Gastroenterol Hepatol 2023;8(1):20–30; ²Vinciguerra et al. Acta Diabetol 2013;50(3):443–449; ³Pantalone et al. BMJ Open 2017;7(11):e017583; ⁴Schienkiewitz et al. BMC Public Health 2012;12:658; ⁵Arinsoy et / al. J Ren Nutr 2016;26(6):373–379; ⁶Yim & Yoo. Clin Exp Pediatr 2021;64(10):511–518. / CKD=chronic kidney disease; CVD=cardiovascular disease; MASH=metabolic dysfunction-associated steatohepatitis; MASLD=metabolic dysfunction-associated steatotic liver disease; T2D=type 2 diabetes.
Visuals: Diagram: a three-set nested and overlapping Venn/Euler diagram with semi-transparent filled circles. Outer large circle, blue #00427A at about 25% opacity, labelled 'People who are overweight or have obesity'. Overlapping grey-green circle #08312A at about 24% opacity, labelled 'MASLD' (inside, dark green text). Inner dark circle, black at about 10% opacity, labelled 'MASH'. Circle T2D, yellow #FFB500 at about 25% opacity, labelled 'T2D' in dark gold #BF8800. Circle CVD, grey #898D8D at about 26% opacity, labelled 'CVD'. Circle CKD, red #EE462B at about 25% opacity, labelled 'CKD' in red text. Thin dark outlines on the circles. Organ icons with callouts: liver icon (brown-orange, small green spot) with '~75%¹' and a leader line to the MASLD circle; second liver icon with '~34%¹' and a black leader line to the MASH circle; pancreas icon (yellow) with '~15–30%²˒³' and a leader line with yellow dot to the T2D circle; heart icon (red) with '~10–15%⁴' and a grey dot leader to the CVD area; kidney icons (red) with '~20%⁵˒⁶' and a red dot leader to the CKD circle. Callout percentages are printed values, not estimates. Photograph: black-and-white photo of a large exhibition booth at ObesityWeek, viewed from below at an upward angle; a hanging sign panel reads 'See Obesity, Think Liver' and 'Boehringer Ingelheim' logo at left; a monitor at lower centre shows a woman in a grey top; overhead truss and bright ceiling lights; lighting is bright spotlighting against a dark ceiling; monochrome with no tint; boxed with square corners, not cropped beyond its frame.
Slide 27
Primary care leads;
specialty still emerging
~90% of GLP-1 prescriptions for weight management are driven by primary care providers 1,a
Identified as primary care providers
Nurse practitioner/ Physician assistant
Primary care physician
Osteopathic physician
Endocrinologist
Other specialist
40%
37%
11%
5%
7%
Image is illustrative, no associations implied.
a Primary care physicians include internal medicine, general practice, and family practice. Other specialists include cardiology, obstetrics/gynecology, general surgery, emergency medicine, geriatrics, and pediatrics.
Sources: 1IQVIA National Prescription Audit, MAT October 2025.
GLP-1=glucagon-like peptide-1.
27
Visuals: Donut chart with no axes and no title. Series: Nurse practitioner/Physician assistant 40% (black #000000, about 40% of the ring, from 12 o'clock clockwise to about 4 o'clock); Primary care physician 37% (dark grey #595959, bottom-left arc); Osteopathic physician 11% (teal #23AEB7, left arc); Endocrinologist 5% (amber #FFB500, upper-left arc); Other specialist 7% (mid grey #898D8D, top-left arc between 11 and 12 o'clock). Data labels sit inside each segment: 40% white bold, 37% white bold, 11% black bold, 5% black bold, 7% white bold. Donut hole is white, about 50% of outer diameter, centred at roughly x 27.5%, y 58.5%. Legend: four-row list with coloured square swatches (black, grey #898D8D, teal #23AEB7, amber #FFB500, grey #898D8D) plus text labels; the first three items are enclosed by a dashed rounded-rectangle outline in dark grey, about 1.2 pt. A thin black line with a small filled arrowhead points from the caption Identified as primary care providers down-left toward the dashed outline. Photograph: a smiling man with a short beard and short hair, seen from the waist up, wearing a light polo shirt, looking up and to the right, in front of a tall building with rows of windows; the image is black-and-white with mid to light greys; framing is a medium shot, cropped at the top of the head area on the right side; the photo is boxed (rectangular, no border) and its lower part fades to white through a gradient overlay. Logo: Zeal& Zealand Pharma logo at bottom left made of six coloured circles reading Z (blue #1F5FA8), E (grey), A (yellow), L (teal), & (red-orange), with ZEALAND PHARMA in small bold caps below. Background decoration: a faint pale teal gradient swoosh in the top-right corner.
Slide 28
Two distinct segments, / two focus areas / Prescriber-driven / Specialist-driven prescriptions focusing on benefits of / treating comorbidities and health impact of weight loss / Objectives: / 1 Comorbidity risk reduction and health outcomes / 2 Relative weight loss / 3 Tolerability and user experience (to improve persistence) / 4 Convenience of treatment / Consumer-driven / Consumer-driven primary care prescriptions / focusing on desired weight loss and user experience / Objectives: / 1 Desired weight loss / 2 Tolerability and user experience / 3 Health outcomes / 4 Convenience of treatment / 28
Visuals: Two line-art icons of a person in outline style, drawn in thin teal #23AEB7 strokes with no fill. The left icon (x 6.9%, y 25.3%, w 7.2%, h 14.7%) is a female doctor with shoulder-length hair, a face outline, a stethoscope hanging around the neck and a white coat outline, shown in a faded state at roughly 30% opacity. The right icon (x 53.2%, y 24.7%, w 7.3%, h 14.9%) is a male figure with short hair, a face outline, neck and shoulders cropped at the bottom edge, in full teal strokes. Two rounded-rectangle cards are filled #23AEB7 at 5% opacity (appearing as very pale aqua #F0FAFA) with no border. Two dashed horizontal divider lines in teal, the left one faded, sit under each description (left x 7.0%, y 54.6%, w 38.8%; right x 53.4%, y 54.6%, w 38.8%). The top-right corner carries a soft aqua-to-white light gradient glow as a decorative background image (covers the slide). Numbered list markers 1 to 4 are bold teal figures. The ZEAL& logo is a bottom-left multicolour badge: blue, grey, yellow, teal and red circles with white letters Z, E, A, L and ampersand, above the word ZEALAND PHARMA in small grey capitals.
Slide 29
Healthier version of themselves,
not healthiest
Decisions driven by more than clinical needs
Physical
61% of users in the U.S. self-refer1
Unprecedented willingness to pay
out of pocket
Social
Highly individualized and
cyclical journeys
Emotional
Source: 1Ipsos Obesity and Cardiometabolic Therapy Monitor Q2 2025.
29
Visuals: A circular cycle diagram in the left panel: a thick, semi-transparent white ring (about 17% to 39% of width, 37% to 81% of height) with three white circular nodes on it, at the top (Physical, with a black outline icon of a standing person), lower left (Social, with a black outline icon of three people) and lower right (Emotional, with a black outline icon of a frowning face). Labels Physical, Social and Emotional in bold teal sit beside their nodes. Right column: three teal bars, each with a white line icon at its left: top a head-and-shoulders person outline beside the text '61%' and the sentence; middle a white outline wallet icon; bottom a grid of small person outline icons with one larger circled person in the middle. Background photograph/graphic: a faint pale cyan gradient swash in the top-right corner, otherwise none. No charts or tables.
Slide 30
Desired weight loss contradicts
Weight loss Olympics
>80%
of GLP-1
users
want to lose
20%
up to
of their body
weight
20% want to
lose 1–9%
Weight loss
goals of current
GLP-1 users
2% are unsure
3% want to
lose >30%
14% want to
lose 21–30%
63% want to
lose 10–20%
Source: LifeSci Capital Survey May 2024 (N=819).
GLP-1=glucagon-like peptide-1.
30
Visuals: Donut chart titled 'Weight loss goals of current GLP-1 users' (centre label), showing the share of current GLP-1 users by desired weight loss. Segments, clockwise from top: 20% want to lose 1–9% (dark grey #404040, about 20%, upper-left arc from about 10 to 11 o'clock); 63% want to lose 10–20% (black #000000, about 63%, the large arc from the top round the right side to about 5 o'clock); 14% want to lose 21–30% (teal #23AEB7, about 14%, lower-left arc); 3% want to lose >30% (amber #FFB500, about 3%, small arc at about 8 o'clock); 2% are unsure (grey #898D8D, about 2%, thin arc just above the amber). Thin white separators sit between segments. The ring has a pale teal #23AEB7 outer halo at about 23% opacity. Each segment is tied to its label by a thin dashed leader line in the matching colour (grey, black, teal, amber, grey). No axes, no legend, no highlighted points beyond the 63% segment, which is the largest and is labelled in bold black.
Slide 31
GLP-1 efficacy: / real world vs. clinical trials / Real-world use of Wegovy by dose 1 / ONCE-WEEKLY wegovy semaglutide injection 2.4 mg / Users (%) / 100 90 80 70 60 50 40 30 20 10 0 / 14% 16% 17% 20% 33% / 0.25 mg 0.5 mg 1 mg 1.7 mg 2.4 mg / Real-world weight reduction: 7.7% at 1 year 4 / Mean weight loss of 14.9% at Week 68 in Phase 3 STEP 1 trial 2 / Real-world use of Zepbound by dose 1 / zepbound (tirzepatide) injection / Users (%) / 100 90 80 70 60 50 40 30 20 10 0 / 20% 25% 18% 16% 9% 12% / 2.5 mg 5 mg 7.5 mg 10 mg 12.5 mg 15 mg / Real-world weight reduction: 12.4% at 1 year 4 / Mean weight loss of 20.9% at Week 72 in Phase 3 SURMOUNT-1 trial 3 / Sources: 1 IQVIA National Prescription Audit, MAT October 2025; 2 Wilding et al. N Engl J Med 2021;384(11):989–1002; 3 Jastreboff et al. N Engl J Med 2022;387(3):205–216; 4 Real-World GLP-1 Weight-Loss Results Differ From Trials - Medscape - June 10, 2025. / GLP-1RA=glucagon-like peptide-1 receptor agonist. / ZEALAND PHARMA / 31
Visuals: Two vertical bar charts. Left chart: Wegovy real-world use by dose, title 'Real-world use of Wegovy by dose 1'. Y axis titled 'Users (%)', range 0 to 100 in steps of 10, gridlines absent, axis ticks shown. X axis categories 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg (no axis unit title). One series, black columns #000000 on light grey full-height tracks #D9D9D9 reaching 100. Labelled values: 0.25 mg 14%, 0.5 mg 16%, 1 mg 17%, 1.7 mg 20%, 2.4 mg 33%. Highlighted point: the 2.4 mg column is the tallest bar. Callout box inside the chart reads 'Real-world weight reduction: 7.7% at 1 year'. A speech-bubble-style callout below the 2.4 mg column (pointer triangle upward at the 2.4 mg label) reads 'Mean weight loss of 14.9% at Week 68 in Phase 3 STEP 1 trial'. Right chart: Zepbound real-world use by dose, title 'Real-world use of Zepbound by dose 1'. Y axis 'Users (%)', range 0 to 100 in steps of 10. X axis categories 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. One series, teal columns #23AEB7 on pale tracks #DEF3F4 reaching 100. Labelled values: 2.5 mg 20%, 5 mg 25%, 7.5 mg 18%, 10 mg 16%, 12.5 mg 9%, 15 mg 12%. Highlighted point: the 15 mg column with a callout pointer. Rounded callout box reads 'Real-world weight reduction: 12.4% at 1 year' with the 12.4% in teal. Callout below the 15 mg column reads 'Mean weight loss of 20.9% at Week 72 in Phase 3 SURMOUNT-1 trial' with 20.9% and SURMOUNT-1 in teal. Logos: Wegovy logo (ONCE-WEEKLY wegovy semaglutide injection 2.4 mg, wordmark in blue-to-magenta gradient, 2.4 mg in magenta) and Zepbound logo (zepbound wordmark in blue and green with arrow chevrons, (tirzepatide) injection in grey). Zealand Pharma logo bottom-left: four coloured circles with letters Z E A L & in dark blue, grey, yellow, teal, red, with ZEALAND PHARMA beneath.
Slides 32 to 119 continue in the full text file.
Download this deck
The hosted PDF of every library deck is free for readers of the SlideDeck Co newsletter. Join with your email and the viewer and download appear here.
Preparing a results presentation or business update of your own? The SlideDeck Co Standard Deck is a slide library for business reviews, updates and plans.






